Park Medi World
Market cap ₹10,282 Cr
- P/E
- 38.96
- Day range
- ₹235.76 – ₹241.16
- 52-week range
- ₹138.10 – ₹305.00
- Volume
- 4.83 L
- Open
- ₹240.01
- Prev close
- ₹240.01
Latest results · Q2 FY27(consolidated)Revenue ₹511 CrProfit ₹54 CrMargin 10.7%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
PARKHOSPS in NSE indices and F&O
Research profile
Composite 51 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.6%
- Graham no.
- ₹80.52
- vs Graham
- -66.2%
- ROE ÷ P/B
- 3.6%
- Magic Formula
- #317
- FCF yield
- 2.0%
Appears in 7 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Park Medi WorldPARKHOSPS | ₹10,282 Cr | 38.96 | 4.90 | 17.8% | 19.0% | 20.0% | 0.26 | +24.6% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 7h agoHeadlines about Park Medi World from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 41.3
- Price / Book
- 4.76
- ROE (FY26)
- 17.8%
- ROCE (latest year)
- 19%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹235.15
- Price above
- 50-day
- ₹256.37
- Price below
- 200-day
- ₹245.23
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 348 | 354 | 399 | 410 | 410 | 460 | 476 | 511 |
| Expenses | 265 | 265 | 294 | 297 | 311 | 333 | 350 | 409 |
| Operating Profit | 83 | 88 | 105 | 113 | 99 | 127 | 126 | 102 |
| OPM % | 24% | 25% | 26% | 27% | 24% | 28% | 26% | 20% |
| Other Income | 15 | 9 | 7 | 8 | 9 | 8 | 8 | 10 |
| Interest | 16 | 16 | 15 | 15 | 15 | 14 | 10 | 14 |
| Depreciation | 15 | 16 | 15 | 15 | 15 | 18 | 19 | 21 |
| Profit before tax | 67 | 66 | 82 | 91 | 78 | 103 | 105 | 76 |
| Tax % | 32% | 20% | 20% | 14% | 32% | 26% | 16% | 29% |
| Net Profit | 46 | 52 | 66 | 79 | 53 | 77 | 89 | 54 |
| EPS in Rs | ₹1.19 | ₹1.17 | ₹1.51 | ₹1.91 | ₹1.17 | ₹1.64 | ₹1.91 | ₹1.21 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-22 days since Mar 2021
-43 days since Mar 2021
+13 days since Mar 2021
-79 days since Mar 2021
-12 days since Mar 2021
Strengths, risks & growth
Park Medi World engaged in the business of, inter alia, establishing, maintaining and running hospitals, nursing homes, clinics, dispensaries, maternity homes, child welfare, family planning etc.(Source : 202503 Annual Report Page No:320)
Strengths
None flagged by the checklist.
Risks
- Though the company is reporting repeated profits, it is not paying out dividend
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +17%
- 3 Years
- +10%
- TTM
- +23%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +11%
- 3 Years
- +5%
- TTM
- +15%
Return on Equity
- 10 Years
- —
- 5 Years
- +24%
- 3 Years
- +19%
- Last Year
- +17%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 82.89% | 82.89% | 82.89% | 82.89% | 0.00 pp |
| FII | 1.28% | 0.86% | 0.82% | 0.88% | +0.06 pp |
| DII | 8.58% | 8.95% | 8.95% | 8.23% | -0.72 pp |
| Government | 0.20% | 0.30% | 0.00% | 0.00% | 0.00 pp |
| Public | 7.06% | 6.98% | 7.33% | 8.00% | +0.67 pp |
Filed with NSE for Sept 2026: promoters 82.90%, public 17.10%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 5.39% (-0.27 pp)- Promoters82.9%
- Foreign institutions0.9%
- Mutual funds5.4%
- Insurance0.4%
- Other domestic institutions2.5%
- Retail3.0%
- Others5.0%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Kotak Multi Asset Allocation Fund | 1.90% | 1.34% | -0.44 pp |
| Kotak Contra Fund | 0.71% | 1.45% | -0.35 pp |
| Kotak ELSS Tax Saver Fund | 0.56% | 0.97% | -0.24 pp |
| Kotak Consumption Fund | 0.43% | 2.67% | -1.09 pp |
| Kotak Special Opportunities Fund | 0.33% | 1.91% | -1.19 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 226 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 42.7%
- Downside volatility
- 38.3%
- Worst 5% of days
- 4.2%
- Average of that tail
- 5.5%
- Max drawdown (1Y)
- 28.1%
- Below its peak
- 20.5%
Against the market
- Beta vs Nifty 50
- 0.82
- Correlation
- 0.29
- Relative strength (3M)
- -17.8%
- ATR (14)
- 4.9%
Return
- Return 1M
- +1.0%
- Return 3M
- -14.0%
- Return 6M
- -0.7%
- Return 1Y
- —
- vs 200-day average
- -2.9%
Momentum
- RSI (14)
- 45.2
- MACD histogram
- 2.18
- Stochastic %K
- 42.1
- ADX (14)
- 32.7
- +DI / −DI
- 19.7 / 30.0
- Money flow index
- 21.5
Participation
- Delivery (20d avg)
- 49.1%
- vs its 60-day baseline
- -3.9 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- +0.3%
- 52-week position
- 61 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.
- Free cash flow
- ₹209 Cr
- FCF yield
- 2.0%
- Net debt
- ₹127 Cr
- Net debt / equity
- 0.06
- EV / sales
- 5.61
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
Company announcements
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Intimation regarding closure of trading window
Voting Results and Consolidated Scrutinizer's Report on E-voting at 15th Annual General Meeting held on September 22, 2026
Summary of the proceedings of 15th Annual General Meeting of the Company held on September 22, 2026
Press Release titled Park Group of Hospitals Wins Three Honours at Healthcare Pioneers of Delhi 2026
Cancellation of Schedule of Investor/Analyst Meeting
Wholly-owned subsidiary of the Company has entered into operation and management agreement with Axis Educational Society
Incorporation of Wholly Owned Subsidiary
Meeting with Analysts/Investors
Voting results with respect to Postal Ballot notice dated August 03, 2026
Incorporation of Wholly Owned Subsidiary
Outcome of Board Meeting held on August 31, 2026
Newspaper Advertisement regarding Notice of the 15th AGM containing e-voting information and dispatch details
Letter to the Shareholders containing weblink of Annual Report and Notice of AGM for the Financial year 2025-2026
Filed with BSE (scrip 544645); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026SlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
Credit ratings
- Rating update · 4 Nov 2025 from crisil
- Rating update · 24 Oct 2025 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 13 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Park Medi World: common questions
Answered from the figures on this page.